एटोडोलैक और टोफासिटिनिब का इंटरैक्शन

Promptly evaluate patients treated with XELJANZ/XELJANZ XR who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis or taking NSAIDs) and who present with new onset abdominal symptoms for early identification of gastrointestinal perforation [see Adverse Reactions (6.1) ] .

In these studies, many patients with RA received background therapy with nonsteroidal anti-inflammatory drugs (NSAIDs).